A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(33 sites)

United States

Research Site, Anniston, Alabama

Research Site, Birmingham, Alabama

Research Site, La Jolla, California

Research Site, Sacramento, California

Research Site, Iowa City, Iowa

Canada

Research Site, Hamilton, Ontario

Research Site, Sherbrooke, Quebec

China

Research Site, Beijing

Research Site, Shanghai

Research Site, Wuhan

France

Research Site, Bordeaux

Research Site, Montpellier

Research Site, Nancy

Research Site, Paris

Research Site, Strasbourg

Research Site, Toulouse

Germany

Research Site, Cologne

Research Site, Erlangen

Research Site, Magdeburg

Japan

Research Site, Bunkyō City

Research Site, Kita-gun

Research Site, Kitakyushu-shi

Research Site, Kyoto

Research Site, Nagasaki

Netherlands

Research Site, Amsterdam

Research Site, Leiden

Spain

Research Site, Mérida

Research Site, Seville

Research Site, Valladolid

United Kingdom

Research Site, Glasgow

Research Site, London

Research Site, Southampton